Neural Stem Cell-mediated Enzyme/prodrug Therapy for Glioma Preclinical Studies Reviews
Grade 4 astrocytoma, termed glioblastoma multiforme (GBM) is one the virtually aggressive malignancies known to homo. Despite intensive therapies, the median survival has remained approximately 15 months. One of the major challenges to the treatment of CNS malignancies is the blood brain bulwark (BBB). The bulwark is designed to be incredibly selective, which means few therapeutics given to patients volition reliably arrive at the site of the malignancy. To overcome the BBB and low blood flow that tends to occur inside these tumors, various biodegradable materials, polymers and nanoparticles that can slowly release therapeutics at the site of the tumor have been developed. In the by, various chemotherapies have been attempted to be delivered in this fashion (
). The major trouble with straight treatment of tumors is the depression amount of diffusion and inefficient delivery of therapeutics. At that place have been attempts at enhanced commitment using convection based therapies, which until this bespeak accept not generated significant survival advantage in patients. Furthermore, the diffuse nature of the tumor means it may spread far from the treatment site. It is for these reasons that a carrier with a loftier amount of versatility and tumor-homing capability is urgently needed.
Beginning with a critical discovery in 2000, it was demonstrated that neural stem cells (NSCs) have intrinsic glioma-tropic properties, even to distant sites (
Aboody et al., 2000
- Aboody K.Southward.
- Brown A.
- Rainov Due north.G.
- Bower K.A.
- Liu S.
- Yang W.
- Small J.E.
- Herrlinger U.
- Ourednik 5.
- Blackness P.1000.
- Breakefield 10.O.
- Snyder Due east.Y.
Neural stem cells brandish all-encompassing tropism for pathology in developed brain: bear witness from intracranial gliomas.
- Crossref
- PubMed
- Scopus (982)
- Google Scholar
). Since this initial finding, NSCs take been manipulated in a number of ways to elicit anti-cancer effects. Outset, NSCs can be engineered to produce unlike genes. In a pioneering preclinical written report, Dr. Aboody's laboratory generated an NSC cell line conveying cytosine deaminase (CD). Afterwards systemic handling with the pro-drug Gancyclovir (GCV), the suicide gene converts the GCV into its toxic di (and tri) phosphate form only where the NSCs accept migrated. This has provided meaning efficacy in a pre-clinical model of GBM while preventing off-target toxicity (
Aboody et al., 2013
- Aboody K.South.
- Najbauer J.
- Metz Grand.Z.
- D'Apuzzo M.
- Gutova M.
- Annala A.J.
- Synold T.W.
- Couture L.A.
- Blanchard S.
- Moats R.A.
- Garcia E.
- Aramburo South.
- Valenzuela V.Five.
- Frank R.T.
- Barish North.Due east.
- Brown C.E.
- Kim S.U.
- Badie B.
- Portnow J.
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
- Crossref
- PubMed
- Scopus (164)
- Google Scholar
). A phase I clinical trial utilizing this approach has recently completed accrual (Clinical Trial Identifier — NCT02015819). Other groups have generated NSC cell lines with other anti-cancer agents. NSCs expressing the anti-tumor molecule TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) have recently come back into focus after groups accept been able to sensitize glioblastoma cells to TRAIL using a number of novel compounds such as the cardiac glycoside lanatoside C and the histone deacetylase inhibitor MS-275 (
,
). Both therapies are idea to function past influencing culling death receptor (DR) expression on the surface of glioblastoma cells, thus providing alternative targets for TRAIL induced cell expiry.
Other than directly modifying the NSC, these cells tin also be loaded with therapeutic cargo. Our grouping had previously loaded NSC with mesoporous nanoparticles containing doxorubicin, attached via a pH sensitive linker (
Cheng et al., 2013
- Cheng Y.
- Morshed R.
- Cheng S.H.
- Tobias A.
- Auffinger B.
- Wainwright D.A.
- Zhang L.
- Yunis C.
- Han Y.
- Chen C.T.
- Lo Fifty.W.
- Aboody K.S.
- Ahmed A.U.
- Lesniak M.S.
Nanoparticle-programmed self-destructive neural stalk cells for glioblastoma targeting and therapy.
- Crossref
- PubMed
- Scopus (59)
- Google Scholar
). This targeted release of chemotherapeutics had significant impact on animal survival in a mouse model of glioma. Other nanoparticles take likewise been successfully loaded into NSC, for example another group loaded golden nanorods (AuNR) onto NSC carriers, which enhanced the distribution of the nanoparticles to the tumor tissue (
Mooney et al., 2014
- Mooney R.
- Roma L.
- Zhao D.H.
- Van Haute D.
- Garcia E.
- Kim S.U.
- Annala A.J.
- Aboody Grand.S.
- Berlin J.Yard.
Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy.
- Crossref
- PubMed
- Scopus (115)
- Google Scholar
). Later treatment with near-infrared radiation, the gold nanoparticles convert light to tumor-killing rut, which therapeutic effect covers a significantly larger area than injection of particles alone.
The use of NSC carriers has recently been extended into the loading of adenoviruses. By allowing either the infection or replication merely within cancer cells, the utilise of recently adult conditionally targeted or replicative adenoviruses (CRAds) has become an attractive modality for treatment. This allows for a "1–2 punch" of both oncolysis and enhanced delivery of therapeutics, while as well minimizing astray toxicity. Past loading a conditionally replicative adenovirus (CRAd-Survivin-pk7) onto NSC carriers, nosotros have demonstrated enhanced anti-tumor efficacy compared to viral treatment solitary (
Ahmed et al., 2013
- Ahmed A.U.
- Thaci B.
- Tobias A.L.
- Auffinger B.
- Zhang Fifty.
- Cheng Y.
- Kim C.K.
- Yunis C.
- Han Y.
- Alexiades N.G.
- Fan X.
- Aboody G.South.
- Lesniak M.Due south.
A preclinical evaluation of neural stalk jail cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
- Crossref
- PubMed
- Scopus (64)
- Google Scholar
). Previous studies have been performed to advise this modality of CRAd delivery is efficacious and is currently planned for a phase-I clinical trial.
The route of delivery of NSCs is critical for an efficacious therapy, because the corporeality of NSCs that can make it to the glioma tissue is highly dependent on their road of administration. In murine models of GBM, injection of NSCs contralateral to the tumor site causes their migration and efficient delivery of therapy (
Ahmed et al., 2013
- Ahmed A.U.
- Thaci B.
- Tobias A.L.
- Auffinger B.
- Zhang L.
- Cheng Y.
- Kim C.K.
- Yunis C.
- Han Y.
- Alexiades N.G.
- Fan X.
- Aboody Grand.S.
- Lesniak Thousand.S.
A preclinical evaluation of neural stem cell-based jail cell carrier for targeted antiglioma oncolytic virotherapy.
- Crossref
- PubMed
- Scopus (64)
- Google Scholar
). The problem in human being patients is that intratumoral injections are invasive and troublesome for repeat injections. While intravenous administration of NSCs can still crusade migration to the tumor site, the efficacy of this route remains controversial. Recently, as a way to curtail these limitations, it has been demonstrated that NSC can be delivered intra-nasally and efficiently drift to the tumor tissues. The intranasal route allows for repeat assistants and has higher amounts of NSC migration (
Schmidt et al., 2014
- Schmidt N.O.
- Duhrsen Fifty.
- Reitz M.
- Henze M.
- Sedlacik J.
- Riecken K.
- Fehse B.
- Westphal K.
Repeated intranasal application of neural stem cell-mediated enzym/prodrug therapy using a novel Hsv-thymidine kinase variant improves therapeutic efficiency in an intracranial glioblastoma model.
- Crossref
- Google Scholar
).
These methods of direct treatment to the tumor have advanced significantly from simply administering drugs directly to the tumor site. Stalk cells and the therapies they carry provide a powerful new platform for treating malignancies. The field of cellular carriers is even so in its infancy, and there are nonetheless many obstacles to overcome for this therapy to go successful. Information technology is important to note that the loading of adenoviruses into NSCs enhances survival in a murine model of glioma much amend than virus loaded mesenchymal stem cells (MSC), both of which are tumor tropic carriers (
Ahmed et al., 2011
- Ahmed A.U.
- Tyler K.A.
- Thaci B.
- Alexiades North.G.
- Han Y.
- Ulasov I.V.
- Lesniak Thou.S.
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
- Crossref
- PubMed
- Scopus (105)
- Google Scholar
). This suggests that the trafficking efficacy of carriers might be closely linked to the similarity between the origin of the carrier and the malignancy. Substantial work needs to exist done in understanding what causes different types of carriers to migrate to tissues differentially. With the results of some early clinical trials on the horizon, we will get a clearer motion picture of how efficacious NSCs are as carriers of therapeutics. Through the evolution of both increasingly specific therapeutics and meliorate delivery systems, in that location is a hope that we will see dramatic enhancements in patient outcomes for this terrible illness.
Conflict of Interest
The authors declare no conflicts of interest.
References
- Aboody et al., 2000.
Neural stem cells display extensive tropism for pathology in developed encephalon: evidence from intracranial gliomas.
Proc. Natl. Acad. Sci. U. South. A. 2000; 97 : 12846-12851 - Aboody et al., 2013.
Neural stem prison cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Scientific discipline Translational Medicine. 2013; 5 : 184ra59 - Ahmed et al., 2011.
A comparative study of neural and mesenchymal stalk cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Mol. Pharm. 2011; viii : 1559-1572 - Ahmed et al., 2013.
A preclinical evaluation of neural stalk cell-based cell carrier for targeted antiglioma oncolytic virotherapy.
J. Natl. Cancer Inst. 2013; 105 : 968-977 - Bagci-onder et al., 2013.
Existent-time imaging of the dynamics of death receptors and therapeutics that overcome trail resistance in tumors.
Oncogene. 2013; 32 : 2818-2827 - Cheng et al., 2013.
Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy.
Minor. 2013; 9 : 4123-4129 - Kane et al., 2015.
Sui generis: gene therapy and delivery systems for the handling of glioblastoma.
Neuro Oncol. 2015; 17 Suppl. 2 : ii24-ii36 - Mooney et al., 2014.
Neural stem cell-mediated intratumoral delivery of golden nanorods improves photothermal therapy.
ACS Nano. 2014; 8 : 12450-12460 - Schmidt et al., 2014.
Repeated intranasal application of neural stem cell-mediated enzym/prodrug therapy using a novel Hsv-thymidine kinase variant improves therapeutic efficiency in an intracranial glioblastoma model.
Neuro-Oncology. 2014; xvi - TENG et al., 2014.
Systemic anticancer neural stalk cells in combination with a cardiac glycoside for glioblastoma therapy.
Stem Cells. 2014; 32 : 2021-2032
Article Info
Publication History
Published: August 19, 2015
Identification
DOI: https://doi.org/ten.1016/j.ebiom.2015.08.022
Copyright
© 2015 The Authors. Published past Elsevier Ltd.
User License
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND iv.0) |How you can reuse 
Permitted
For not-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Interpret the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-utilise for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirect- View Large Paradigm
- Download Hello-res paradigm
Source: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(15)00138-3/fulltext
0 Response to "Neural Stem Cell-mediated Enzyme/prodrug Therapy for Glioma Preclinical Studies Reviews"
Post a Comment